BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

NCT ID: NCT06462001

Last Updated: 2024-06-17

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 500 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-10
• Study Completion Date: 2026-12-01

Brief Summary

Instillation of Bacillus of Calmette-Guerin (BCG) into the urinary bladder (intravesical administration) improves rates of disease recurrence and progression after transurethral resection (TUR) of high risk, non-muscle-invasive bladder cancer (NMIBC), but over 30% of people still develop recurrent transitional cell carcinoma (TCC) despite optimal therapy with adjuvant intravesical BCG. Our meta-analysis, including a recent randomised phase 2 trial, suggests that outcomes might be improved further by using an adjuvant intravesical regimen that includes both Mitomycin (MM) and BCG. These promising findings require corroboration in a definitive, large scale, randomised phase 3 trial using standard techniques for intravesical administration.

Conditions

Transitional Cell Carcinoma; Transurethral Resection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Standard Intravesical BCG

Standard intravesical BCG therapy given as per usual standard of care

Group Type: ACTIVE_COMPARATOR

Bacillus Calmette-Guerin Vaccine Intravesical

Intervention Type: BIOLOGICAL

BCG (Oncotice) is administered intravesically as per usual standard of care

Arm B: Experimental BCG + MM

Combination therapy with BCG and MM, given on specific protocol sessions

Group Type: EXPERIMENTAL

Bacillus Calmette-Guerin Vaccine Intravesical

Intervention Type: BIOLOGICAL

BCG (Oncotice) is administered intravesically as per usual standard of care

Mitomycin

Intervention Type: DRUG

MMC is administered intravesically as per usual standard of care

Interventions

Bacillus Calmette-Guerin Vaccine Intravesical

BCG (Oncotice) is administered intravesically as per usual standard of care

Intervention Type: BIOLOGICAL

Mitomycin

MMC is administered intravesically as per usual standard of care

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Males or females with confirmed high grade pTa or stage pT1 (any grade) non-muscle invasive bladder cancer on initial or re-resection histology (concurrent carcinoma in situ is allowed).

2. Age ≥ 18 yrs

3. No macroscopically visible disease at cystoscopy within 8 weeks prior to randomisation. This may either be the initial TURBT at which the primary tumour was completely resected, or a planned second cystoscopy and/ or re-resection done within 8 weeks of the initial TURBT.

4. ECOG Performance Status of 0-2

5. Adequate bone marrow, renal and liver function confirmed by pre-randomisation blood tests.

6. Study treatment both planned and able to start within 4 weeks of randomisation

7. Is willing to complete HRQL questionnaires or is unable to complete them because of literacy, insufficient English or limited vision

8. Willing and able to comply with all study requirements, including treatment, timing and/or nature of all required assessments

9. Signed, written informed consent

Exclusion Criteria

1. Contraindications or hypersensitivity to investigational products, BCG and MM

2. Prior treatment with any other intravesical agent including BCG or MM (excludes single doses given post TURBT)

3. Current or past transitional cell carcinoma (TCC) of the upper urinary tract

4. Prior muscle-invasive (stage T2 or higher) transitional-cell carcinoma of the bladder

5. Bladder dysfunction precluding intravesical therapy e.g. Severe urinary incontinence or overactive or spastic bladder

6. Life expectancy < 3 months

7. Congenital or acquired immune deficiencies, whether due to a concurrent disease (e.g. acquired immune deficiency syndrome (AIDS), leukaemia, lymphoma) or immunosuppressive therapy (e.g. corticosteroids), or cancer therapy (cytotoxic drugs, radiation)

8. Prior radiotherapy of the pelvis

9. Prior or current treatment with radiotherapy-response or biological-response modifiers

10. Clinical evidence of existing active tuberculosis

11. History of another malignancy within 5 years prior to registration. Patients with non-melanomatous carcinoma of the skin are eligible for this study.

12. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.

13. Pregnancy, lactation, or inadequate contraception. Women must be post menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OTHER

Sponsor Role: collaborator

University of Sydney

OTHER

Sponsor Role: collaborator

Nottingham University Hospitals NHS Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dickon Hayne, PhD

Role: STUDY_DIRECTOR

The University of Western Australia

Locations

Nottingham University Hospitals

Nottingham, , United Kingdom

Countries

United Kingdom

Other Identifiers

18UR004

Identifier Type: -

Identifier Source: org_study_id